Agenus (AGEN) Stock Price, News & Analysis

Company Overview

Agenus Inc. (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. Its research programs are designed to activate and direct the immune system against tumors, with an emphasis on therapies that may address immune resistance and improve responses in difficult-to-treat cancers.

The company’s pipeline has included checkpoint inhibitors, cancer vaccines, immune-stimulating adjuvants, bispecific antibodies and other antibody-based therapies. Among its investigational programs are botensilimab, an Fc-enhanced CTLA-4 antibody, and balstilimab, a PD-1 inhibitor. Agenus has evaluated these and other candidates in clinical studies across multiple cancer types, including colorectal cancer and other solid tumors. These products remain investigational unless approved by applicable regulatory authorities.

Agenus was founded in 1994 and was formerly known as Antigenics before adopting the Agenus name in 2011. The company is headquartered in Lexington, Massachusetts, and conducts research and clinical development through operations and collaborations in the United States and internationally. Garo Armen, one of the company’s founders, serves as chairman and chief executive officer.

Key Stats

• Today's Range: $9.62 to $10.31
• 50-Day Range: $5.53 to $9.89
• 52-Week Range: $2.71 to $10.31
• Volume: 663,219 shs
• Average Volume: 1.95 million shs
• Market Capitalization: $439.18 million
• P/E Ratio: 3.76
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Moderate Buy

Agenus Stock Analysis - MarketRank™

Agenus scored higher than 64% of companies evaluated by MarketBeat, and ranked 299th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Agenus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Agenus has a consensus price target of $24.50, representing about 149.6% upside from its current price of $9.82.

Amount of Analyst Coverage

Agenus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Agenus are expected to decrease in the coming year, from ($0.30) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agenus is 3.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agenus is 3.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.09.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.11% of the float of Agenus has been sold short.

Short Interest Ratio / Days to Cover

Agenus has a short interest ratio ("days to cover") of 7.68.

Change versus previous month

Short interest in Agenus has recently increased by 1.71%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agenus does not currently pay a dividend.

Dividend Growth

Agenus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.57

News Sentiment

Agenus has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Agenus this week, compared to 4 articles on an average week.

Search Interest

Only 8 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

6 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Agenus insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.50% of the stock of Agenus is held by insiders.

Percentage Held by Institutions

61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AGEN
• CIK: 1098972
• Web: agenusbio.com
• Phone: (781) 674-4400
• Fax: 781-674-4200
• Employees: 81
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Agenus: $24.50
• High Price Target: $40.00
• Low Price Target: $14.00
• Potential Upside/Downside: +149.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.58
• Trailing P/E Ratio: 3.81
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $120 thousand
• Net Margins: 69.33%
• Pretax Margin: 69.31%
• Return on Equity: -47.68%
• Return on Assets: 57.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $114.20 million
• Price / Sales: 3.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.17) per share
• Price / Book: -1.20

Miscellaneous

• Outstanding Shares: 45,160,000
• Free Float: 42,226,000
• Market Cap: $443.47 million
• Optionable: Optionable
• Beta: 1.38